MannKind Corp
MNKD
NASDAQ
Biotechnology
$3.85
USD
+0.12 (+3.22%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $1.23B
Volume 2.9M
Revenue
$393.63M
TTM
+30.5%
YoY
Gross Margin
75%
TTM
+0.6%
YoY
Net Income
$-43.61M
TTM
-233.0%
YoY
Operating Cash Flow
$-8.05M
TTM
-123.3%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 76.5 | 82.1 | 112.0 | 90.2 | 109.4 |
YoY Growth | +5.7% | +17.2% | +45.8% | +15.1% | +42.9% |
Cost of Revenue | 20.6 | 20.2 | 29.7 | 17.5 | 29.5 |
Gross Profit | 56.0 | 61.9 | 82.3 | 72.7 | 79.8 |
Selling, General & Administrative | 31.6 | 29.1 | 58.4 | 54.1 | 58.3 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 45.3 | 43.2 | 90.0 | 75.7 | 80.7 |
Operating Income | 10.7 | 18.8 | -7.7 | -3.0 | -0.8 |
EBITDA | 12.7 | 20.8 | -1.7 | 3.4 | 5.6 |
Other Income / Expense | -5.4 | -6.3 | -1.0 | -2.4 | -4.5 |
Total Other Income / Expense | -9.7 | -11.0 | -13.2 | -13.4 | -18.3 |
Income Before Income Taxes | 0.9 | 7.8 | -20.9 | -16.4 | -19.1 |
Income Taxes | 0.3 | -0.2 | -5.0 | 0.3 | -0.1 |
Net Income | 0.7 | 8.0 | -15.9 | -16.6 | -19.0 |
Consolidated Net Income / Loss | 0.7 | 8.0 | -15.9 | -16.6 | -19.0 |
Net Income Attributable to Common Shareholders | 0.7 | 8.0 | -15.9 | -16.6 | -19.0 |
Basic EPS | $0.00 | $0.03 | -$0.05 | -$0.05 | -$0.06 |
Diluted EPS | $0.00 | $0.03 | -$0.05 | -$0.05 | -$0.06 |
Basic Shares Outstanding | 305.0M | 306.8M | 307.3M | 308.3M | 309.2M |
Diluted Shares Outstanding | 311.5M | 311.6M | 312.4M | 308.3M | 309.2M |